Monday, October 25, 2010

Amgen's Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year

Third Quarter 2010 Adjusted Earnings Per Share Decreased 9 Percent to $1.36

Third Quarter 2010 GAAP Earnings Per Share Decreased 6 Percent to $1.28

2010 Revenue and Adjusted EPS Guidance Reaffirmed

THOUSAND OAKS, Calif., Oct 25, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) reported revenue unchanged for the third quarter of 2010 at $3,816 million versus $3,812 million for the third quarter of 2009. 

Read the rest of this entry

Posted in Press Releases

Wednesday, October 20, 2010

Breakaway From Cancer(R) Launches 'Striking the Balance' Podcast Series to Inspire Action and Change Across the Cancer Continuum

THOUSAND OAKS, Calif., Oct 20, 2010 /PRNewswire via COMTEX/—Amgen announced today the launch of the Breakaway from Cancer(R) initiative’s "Striking the Balance" podcast series. The series presents the best moments from a dynamic, first-of-its-kind roundtable event held with Amgen’s four nonprofit Breakaway from Cancer partner organizations at the 2010 American Society of Clinical Oncology (ASCO) annual meeting.

Read the rest of this entry

Posted in Press Releases

Wednesday, October 20, 2010

Amgen Announces Webcast of 2010 Third Quarter Financial Results

THOUSAND OAKS, Calif., Oct 20, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) today announced that it plans to report its third quarter financial results on Monday, Oct. 25, 2010 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team.

Read the rest of this entry

Posted in Press Releases

Monday, October 18, 2010

Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today

THOUSAND OAKS, Calif., Oct 18, 2010 /PRNewswire via COMTEX/—Amgen (Nasdaq: AMGN) will review the results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy) and will discuss how these results inform the appropriate use of erythropoiesis-stimulating agents (ESAs) for chronic renal failure (CRF) patients at today’s meeting of the Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC).

Read the rest of this entry

Posted in Press Releases